226950.KQ KOE
OliX Pharmaceuticals,Inc
1W: +13.7%
1M: +10.7%
3M: -30.1%
YTD: -9.5%
1Y: +124.2%
3Y: +687.1%
₩116,800.00 ($87.00)
-100.00 (-0.09%)
Weekly Expected Move ±12.2%
₩88232
₩102516
₩116800
₩131084
₩145368
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$15.9B
+43.3% ▲
Capital Expenditures
$1.3B
+91.0% ▲
5Y CAGR: +1.7%
Free Cash Flow
-$17.2B
+59.3% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$2.5B
+130.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$29.2B | -$21.9B | -$19.1B | -$40.7B | -$15.7B |
| Depreciation & Amort. | $1.6B | $2.1B | $2.6B | $2.6B | $2.5B |
| Stock-Based Comp. | $1.9B | $1.4B | $1.2B | $1.2B | $0 |
| Change in Working Capital | $2.4B | -$8.5B | -$7.2B | -$1.8B | $9.7B |
| Other Non-Cash Items | $6.0B | -$2.8B | $1.2B | $10.6B | -$12.3B |
| Operating Cash Flow | -$19.1B | -$30.7B | -$21.2B | -$28.0B | -$15.9B |
| — Investing Activities — | |||||
| Capital Expenditures | -$26.3B | -$2.5B | -$8.8B | -$14.1B | -$1.9B |
| Acquisitions (Net) | $1.8B | $181M | $0 | $0 | $740M |
| Investment Purchases | -$20.5B | -$119.4B | -$66.0B | -$50.5B | -$207.2B |
| Investment Sales | $61.9B | $68.3B | $109.1B | $60.5B | $102.9B |
| Other Investing | $355M | -$1.3B | $40M | $5.0B | $528M |
| Investing Cash Flow | $17.2B | -$54.8B | $34.4B | $974M | -$104.9B |
| — Financing Activities — | |||||
| Net Debt Issuance | $24.5B | $57.0B | -$5.5B | $19.7B | $117.6B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$3.2B | -$58.0B | -$1.1B | -$1.1B | -$724M |
| Financing Cash Flow | $26.6B | $56.0B | -$6.1B | $18.5B | $123.8B |
| Net Change in Cash | $23.0B | -$29.4B | $7.1B | -$8.1B | $2.5B |
| Cash End of Period | $34.3B | $4.9B | $12.0B | $3.9B | $6.4B |
| Free Cash Flow | -$45.3B | -$33.2B | -$30.2B | -$42.1B | -$17.2B |